top of page

Targeted Oncology First Patient With VEGFRi-Associated Hand-Foot Skin Reaction Enrolled in NOVA-II

Jordyn Sava November 10, 2022 Part 2 of the NOVA-II phase 2 trial evaluating OQL011 has enrolled the first patient with cancer with VEGFR inhibitor-associated hand-foot skin reaction.

The first patient in has been enrolled in part 2 of the phase 2 NOVA-II clinical trial (NCT04088318) evaluating OQL011, a topical ointment for the management of vascular endothelial growth factor receptor (VEGFR) inhibitor-associated hand-foot skin reaction (HFSR) in patients with cancer, according to OnQuality Pharmaceuticals.1

OQL011 is a proprietary ointment which targets the key pathway of VEGFR inhibitor-associated HFSR. The agent has potential to improve or restore VEGF signaling and alleviate HFSR symptoms.

"Our team is delighted to start part 2 of the NOVA-II clinical trial to address the unmet need of cancer-therapy-induced skin toxicities," said Hong Tang, MD, chief medical officer and co-founder of OnQuality Pharmaceuticals, in the press release. "OQL011 generated positive initial findings in part 1 of the phase 2 study and we look forward to advancing the part 2 study to determine the optimal dosage of OQL011 for phase 3."


bottom of page